The landmark FDA approval of Biogen / Eisai’s aducanumab (Aduhelm) in 2021 has had a minimal effect on treatment dynamics in AD owing to the lack of reimbursement and the controversy surrounding…
Renal anemia is a common complication of chronic kidney disease (CKD). Although there are treatments for the disease, physicians, patients, and healthcare systems have concerns about their…
Epilepsy, which afflicts approximately 4.7 million people in the major markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on…
Vaccination programs have had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing childhood and adult…
The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) continues to fragment as newer entrants (e.g., Novartis’s Kesimpta, Bristol Myers Squibb’…
The asthma therapy market consists of many well-established treatments, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s…
The high incidence, long treatment duration, and multiple lines of therapy in the treatment of breast cancer represent strong commercial opportunity for drug development. The CDK4/6 inhibitors (…
The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens,…
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss due to the targeting of anagen hair follicles by the host immune system. The primary…
The rising rates of antimicrobial resistance (AMR) have created an emergent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Since the emergence of the…
Chronic kidney disease (CKD) refers to a set of heterogenous disorders that affect the structure and function of the kidneys. The CKD drug market comprises a wide variety of antihypertensive…
Chemotherapy remains the cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the metastatic setting. The colorectal cancer treatment landscape has…
Hepatocellular carcinoma remains a challenging disease with a complex underlying etiology. While angiogenesis inhibitors including Nexavar (Bayer / Amgen), Stivarga (Bayer), Lenvima (Eisai / Merck…
In June 2021, Biogen / Eisai’s anti-Aβ MAb Aduhelm received accelerated approval from the FDA for the treatment of Alzheimer’s disease (AD), making it the first potential DMT approved for this…
The unipolar depression therapy market is crowded and highly genericized. The prominent use of drugs such as selective serotonin reuptake inhibitors (SSRIs) as early-line treatments contributes to…